Xoma: A Lower Risk Way Of Investing In Biotech Fri, 10 Nov 2017 22:14:00 +0000 Biotech stocks have been big winners this year. But since they can lose 50% in a single day, readers have asked if there is a "safer" way to invest. Bruce Pile tells us about Ligand Pharmaceuticals and Xoma Corp., two biotechs that do not bet the whole company on a single drug candidate.
Xoma beats 3Q profit forecasts Mon, 06 Nov 2017 22:28:10 +0000 The Berkeley, California-based company said it had net income of $1.98 per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference Tue, 19 Sep 2017 11:00:00 +0000 BERKELEY, Calif., Sept. 19, 2017-- XOMA Corporation, a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced that Jim Neal, Chief Executive Officer, will present ...
ETFs with exposure to XOMA Corp. : September 7, 2017 Thu, 07 Sep 2017 18:17:17 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to XOMA Corp. Here are 5 ETFs with the largest exposure to XOMA-US. Comparing the performance and risk of XOMA Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
Today's Research Reports on Stocks to Watch: Insmed Inc. and XOMA Corporation Wed, 06 Sep 2017 12:10:00 +0000 NEW YORK, NY / ACCESSWIRE / September 6, 2017 / XOMA and Insmed both saw their shares blast off on Tuesday. XOMA gained nearly 44% after being upgraded by Wedbush on account of the company announcing that ...
[$$] Novartis Deal Could Send Xoma Stock to $19 Wed, 06 Sep 2017 11:20:00 +0000 Xoma (XOMA:Nasdaq) By Wedbush ($11.18, Sept. 5, 2017) We are upgrading our rating on Xoma to Outperform from Neutral and increasing our 12-month price target to $19 from $9. Due to clinical failures, we thought gevokizumab was shelved but recent cardiovascular clinical success with Novartis’ (NVS) canakinumab apparently created strategic value to have more than one anti-IL-1β treatment--prompting Novartis to license gevokizumab and anti-IL-1β. For gevokizumab, Xoma receives $16 million upfront cash and is eligible for up to $438 million in milestones and high single digit to mid-double-digit percentage tiered royalties on sales.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.85 (median winner: 1.53)
Sales Growth: -36% (median winner: 28%)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.